126 related articles for article (PubMed ID: 28673196)
1. Magnetic Resonance and Ultrastructural Characterization of PEGylation-associated Vacuolation in Nonclinical Models.
Forest T; Xu Q; Kuruvilla S; Vu H; Vlasakova K; Glaab WE; Hines C; Xun S
Toxicol Pathol; 2017 Jul; 45(5):604-613. PubMed ID: 28673196
[TBL] [Abstract][Full Text] [Related]
2. Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products.
Irizarry Rovira AR; Bennet BM; Bolon B; Braendli-Baiocco A; Chandra S; Fleurance R; Garman R; Hutto D; Lane J; Romeike A; Sargeant A; Zimmerman B
Toxicol Pathol; 2018 Aug; 46(6):616-635. PubMed ID: 30092727
[TBL] [Abstract][Full Text] [Related]
3. High molecular weight polyethylene glycol cellular distribution and PEG-associated cytoplasmic vacuolation is molecular weight dependent and does not require conjugation to proteins.
Rudmann DG; Alston JT; Hanson JC; Heidel S
Toxicol Pathol; 2013; 41(7):970-83. PubMed ID: 23788571
[TBL] [Abstract][Full Text] [Related]
4. Adverse vacuolation in multiple tissues in cynomolgus monkeys following repeat-dose administration of a PEGylated protein.
Fletcher AM; Tellier P; Douville J; Mansell P; Graziano MJ; Mangipudy RS; Brodie TA; Achanzar WE
Toxicol Lett; 2019 Dec; 317():120-129. PubMed ID: 31580884
[TBL] [Abstract][Full Text] [Related]
5. Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins.
Bendele A; Seely J; Richey C; Sennello G; Shopp G
Toxicol Sci; 1998 Apr; 42(2):152-7. PubMed ID: 9579027
[TBL] [Abstract][Full Text] [Related]
6. PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
Turecek PL; Bossard MJ; Schoetens F; Ivens IA
J Pharm Sci; 2016 Feb; 105(2):460-475. PubMed ID: 26869412
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, metabolism and distribution of PEGs and PEGylated proteins: quo vadis?
Baumann A; Tuerck D; Prabhu S; Dickmann L; Sims J
Drug Discov Today; 2014 Oct; 19(10):1623-31. PubMed ID: 24929223
[TBL] [Abstract][Full Text] [Related]
8. PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.
Ivens IA; Achanzar W; Baumann A; Brändli-Baiocco A; Cavagnaro J; Dempster M; Depelchin BO; Rovira AR; Dill-Morton L; Lane JH; Reipert BM; Salcedo T; Schweighardt B; Tsuruda LS; Turecek PL; Sims J
Toxicol Pathol; 2015 Oct; 43(7):959-83. PubMed ID: 26239651
[TBL] [Abstract][Full Text] [Related]
9. Evidence for metabolic cleavage of a PEGylated protein in vivo using multiple analytical methodologies.
Elliott VL; Edge GT; Phelan MM; Lian LY; Webster R; Finn RF; Park BK; Kitteringham NR
Mol Pharm; 2012 May; 9(5):1291-301. PubMed ID: 22480236
[TBL] [Abstract][Full Text] [Related]
10. Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates.
Stidl R; Fuchs S; Bossard M; Siekmann J; Turecek PL; Putz M
Haemophilia; 2016 Jan; 22(1):54-64. PubMed ID: 26219204
[TBL] [Abstract][Full Text] [Related]
11. Chronic Toxicology Studies of Basal Insulin Peglispro in Rats and Dogs: A Novel, PEGylated Insulin Lispro Analog with a Prolonged Duration of Action.
Byrd RA; Blackbourne JL; Knadler MP; Schultze AE; Vahle JL
Toxicol Pathol; 2017 Apr; 45(3):402-415. PubMed ID: 28421968
[TBL] [Abstract][Full Text] [Related]
12. Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.
Lee CM; Choi Y; Huh EJ; Lee KY; Song HC; Sun MJ; Jeong HJ; Cho CS; Bom HS
Cancer Biother Radiopharm; 2005 Dec; 20(6):620-8. PubMed ID: 16398614
[TBL] [Abstract][Full Text] [Related]
13. Chemical and enzymatic site specific PEGylation of hGH.
da Silva Freitas D; Mero A; Pasut G
Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
[TBL] [Abstract][Full Text] [Related]
14. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
Youn YS; Lee KC
Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
[TBL] [Abstract][Full Text] [Related]
15. Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc-Porekar V; Zore I; Podobnik B; Menart V
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):242-50. PubMed ID: 18283612
[TBL] [Abstract][Full Text] [Related]
16. Protein carboxyl amidation increases the potential extent of protein polyethylene glycol conjugation.
Li S; Yang Z; Sun X; Tan Y; Yagi S; Hoffman RM
Anal Biochem; 2004 Jul; 330(2):264-71. PubMed ID: 15203332
[TBL] [Abstract][Full Text] [Related]
17. PEGylation and its impact on the design of new protein-based medicines.
Ginn C; Khalili H; Lever R; Brocchini S
Future Med Chem; 2014; 6(16):1829-46. PubMed ID: 25407370
[TBL] [Abstract][Full Text] [Related]
18. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
Balan S; Choi JW; Godwin A; Teo I; Laborde CM; Heidelberger S; Zloh M; Shaunak S; Brocchini S
Bioconjug Chem; 2007; 18(1):61-76. PubMed ID: 17226958
[TBL] [Abstract][Full Text] [Related]
19. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
Wu L; Ho SV; Wang W; Gao J; Zhang G; Su Z; Hu T
Int J Pharm; 2013 Sep; 453(2):533-40. PubMed ID: 23796830
[TBL] [Abstract][Full Text] [Related]
20. In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A; Merkel O; Fink L; Czubayko F; Kissel T; Aigner A
Toxicol Appl Pharmacol; 2009 Apr; 236(1):97-108. PubMed ID: 19371615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
